SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
WillScot issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including revenue of $612 million, net income of $47 million, and Adjusted EBITDA of $228 million, along with a raised full-year 2026 outlook. This is a standard quarterly earnings release disclosure under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →Atlassian disclosed quarterly and fiscal year 2026 financial results, reporting Q4 revenue of $1,766 million (up 28% YoY), cloud revenue of $1,213 million (up 31% YoY), subscription ARR of $6,606 million (up 23% YoY), and a return to GAAP profitability with 12% operating margin.
View raw filing on EDGAR →Priority Technology Holdings issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, including revenue of $262.3 million (9.4% YoY growth), net income of $9.9 million, diluted EPS of $0.12, and adjusted EBITDA of $59.4 million, along with full-year 2026 guidance. The disclosure includes a scheduled earnings conference call and webcast for the same date.
View raw filing on EDGAR →Airship AI Holdings issued a press release announcing its financial and operational results for Q2 2026 (quarter ended June 30, 2026), reporting net revenues of $4.12 million (92% YoY increase), gross profit of $3.09 million (102% YoY increase), and a net loss of $2.4 million.
View raw filing on EDGAR →The filing discloses FHLBNY's "Second Quarter 2026 Operating Highlights," including $153.3 million in net income for Q2, $128 billion in funding to members (up $35 billion from year-end 2025), and $27.5 million allocated to affordable housing initiatives. While presented as a President's Report rather than a formal earnings press release, the core disclosure is quarterly financial results and operational metrics material to shareholders' assessment of the institution's performance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states "Cronos Group Inc. (the 'Company') issued a press release announcing its financial results for its second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The exhibit contains consolidated financial results showing net revenue of $53.0 million (up 58% YoY), gross profit of $28.5 million (up 96% YoY), and Adjusted EBITDA of $13.1 million (up 675% YoY), along with detailed business performance metrics and brand updates.
View raw filing on EDGAR →Hertz Global Holdings issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $2.4 billion (up 10% YoY), GAAP net income of $64 million, and Adjusted Corporate EBITDA of $81 million. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, which is the typical format for earnings disclosures and material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (period ending June 30, 2026) disclosed via press release on August 6, 2026. The filing reports comprehensive financial results including GMV of $1.3 billion (up 37.9% YoY), Total Revenue of $149.7 million (up 51.7% YoY), Net Income of $40.8 million (up 47.7% YoY), and updated FY2026 guidance raising Adjusted Net Income to $185.0 million. The disclosure is material to investors as it presents quarterly operating results, key metrics, and forward guidance.
View raw filing on EDGAR →US Foods disclosed its financial results for the fiscal second quarter ended June 27, 2026 via a press release attached as Exhibit 99.1. The disclosure includes key metrics such as net sales growth of 4.5% to $10.5 billion, net income growth of 22.8% to $275 million, diluted EPS of $1.24, and adjusted EBITDA growth of 10.2% to a record $604 million. This is a standard quarterly earnings release with comprehensive financial results and forward guidance, clearly falling under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →This is a clear earnings release disclosing Immunocore's Q2 2026 financial results, including net product revenues of $115.9 million (18% YoY growth), R&D and SG&A expenses, net loss of $0.8 million, and cash position of $880.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and Item 2.02 explicitly states the Company "issued a press release announcing its financial results for the second quarter ended June 30, 2026." This is a material disclosure affecting investor assessment of the registrant's financial performance and operational progress.
View raw filing on EDGAR →The Trade Desk issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, with detailed GAAP and non-GAAP financial metrics (revenue of $715 million, net income of $64 million, diluted EPS of $0.14), business highlights, and forward guidance for Q3 2026. This is a standard quarterly earnings disclosure furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →Acushnet Holdings Corp. issued a press release on August 6, 2026 announcing quarterly and year-to-date financial results for the period ended June 30, 2026. The disclosure includes detailed net sales figures ($820.0 million for Q2, up 13.8% YoY), net income ($124.8 million, up 65.1% YoY), and Adjusted EBITDA ($208.6 million, up 45.8% YoY), along with updated full-year 2026 guidance. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three and six month periods ended June 30, 2026) issued on August 5, 2026. The Item 2.02 disclosure explicitly states the company "issued a press release...announcing its financial results for the three and six month periods ended June 30, 2026," with the full earnings release attached as Exhibit 99.1. The release includes detailed financial results (net interest income, provision for credit losses, net loss, balance sheet metrics, book value per share) and is material to investors assessing the registrant's financial condition.
View raw filing on EDGAR →Unusual Machines, Inc. disclosed Q2 2026 financial results, including revenue of $16.7 million (687% YoY growth), gross margin of 34.7%, operating loss of $7.8 million, and net loss of $7.8 million ($0.16 per share), along with a shareholder letter from CEO Allan Evans and announcement of a conference call to discuss results.
View raw filing on EDGAR →Applied Optoelectronics issued a press release on August 6, 2026 disclosing financial results for Q2 2026 ended June 30, 2026. The disclosure includes GAAP revenue of $191.9 million (up 86% YoY), gross margin, net loss, and non-GAAP profitability metrics, along with Q3 2026 guidance. This is a standard earnings release attached as Exhibit 99.1 under Item 2.02, and the results are material to investors as they show record revenue for the fifth consecutive quarter and a return to non-GAAP profitability.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Q2 2026 financial results for Establishment Labs Holdings Inc. The filing explicitly states in Item 2.02 that the company "issued a press release announcing the Company's financial results for the three and six months ended June 30, 2026 and recent corporate highlights," with the press release furnished as Exhibit 99.1. The disclosure includes revenue of $67.5 million (up 31.7% YoY), gross margin of 70.6%, and raised full-year guidance to $269-271 million, all material metrics for investor assessment.
View raw filing on EDGAR →Praxis Precision Medicines reported Q2 2026 financial results, including R&D expenses of $69.4M, G&A expenses of $27.5M, a net loss of $83.7M, and a cash position of $1.4B as of June 30, 2026. The disclosure includes operational highlights and anticipated milestones for the company's drug development programs, providing investors with visibility into the company's financial performance and cash runway into 2028.
View raw filing on EDGAR →Kinetik issued a press release on August 5, 2026 announcing financial and operating results for the fiscal quarter ended June 30, 2026, disclosing net income of $123.1 million and $118.0 million for the three and six months ended June 30, 2026, respectively, along with Adjusted EBITDA, Distributable Cash Flow, and Free Cash Flow metrics. The company also raised full year 2026 Adjusted EBITDA guidance to $1.04–$1.1 billion. This is a standard quarterly earnings release with material financial results and forward guidance that would affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →Once Upon a Farm issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing net sales of $85.4 million (42.3% YoY growth), net loss of $5.0 million, and raising full-year 2026 guidance for both net sales ($327–$335 million) and Adjusted EBITDA ($3–$4.5 million). This is a classic earnings release disclosure under Item 2.02, furnished with the press release as Exhibit 99.1 and accompanied by detailed financial statements and management commentary.
View raw filing on EDGAR →The filing discloses quarterly financial results for Q2 2026 via a press release attached as Exhibit 99.1. The press release reports net revenue of $17.2 million (56% growth), gross margin of 78.3%, and raises full-year 2026 guidance to $67–69 million. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and growth trajectory.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 6, 2026. The Item 2.02 disclosure explicitly states "Optimum Communications, Inc. announced its financial results for the quarter ended June 30, 2026" with a press release attached as Exhibit 99.1. The exhibit contains comprehensive financial results including revenue ($2.02 billion), net loss ($291.8 million), Adjusted EBITDA ($785.7 million), and detailed operational metrics. This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →Funko disclosed consolidated financial results for Q2 2026 (three and six months ended June 30, 2026) via press release, reporting net sales of $207.7 million (7% growth), record gross margin of 56.6%, net income of $15.4 million ($0.27 per diluted share), and raising full-year Adjusted EBITDA guidance to $100M–$110M.
View raw filing on EDGAR →Core Natural Resources issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, disclosing net income of $126.5 million ($2.51 per diluted share), adjusted EBITDA of $323.6 million, and free cash flow of $148 million, along with comprehensive operational metrics, segment performance, and forward guidance.
View raw filing on EDGAR →The 6-K body explicitly states it "contains: Exhibit 1: Loma Negra Earnings Release 2Q26," indicating disclosure of second-quarter 2026 financial results. Earnings releases are material events that affect investor assessment of the registrant's financial performance and are commonly furnished as exhibits to Form 6-K by foreign private issuers.
View raw filing on EDGAR →Burford Capital issued a press release and detailed presentation on August 6, 2026, announcing its unaudited financial results for the three and six months ended June 30, 2026 (2Q26 and YTD26). The disclosure includes quarterly financial results, cash position ($733 million), and portfolio performance commentary from the CEO. This is a standard earnings release disclosure under Item 2.02, with exhibits 99.1 and 99.2 containing the press release and presentation respectively.
View raw filing on EDGAR →This is a clear earnings release disclosing Denali Therapeutics' second quarter 2026 financial results. The Item 2.02 filing explicitly states "On August 6, 2026, Denali Therapeutics Inc. (the 'Company') issued a press release announcing its financial results for the second quarter ended June 30, 2026." The press release (Exhibit 99.1) reports Q2 2026 net product revenue of $3.6 million, R&D expenses of $97.0 million, SG&A expenses of $36.3 million, and a net loss of $127.6 million, along with cash position and business highlights. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →Zentalis Pharmaceuticals reported second quarter 2026 financial results and business updates, including cash position of $174.6 million, R&D expenses of $35.2 million, and G&A expenses of $9.2 million, along with material clinical milestones including DENALI enrollment completion, FDA Type D meeting alignment, and ASPENOVA Phase 3 first patient dosed.
View raw filing on EDGAR →Frontdoor issued a press release on August 6, 2026, announcing its financial results for the fiscal quarter ended June 30, 2026. The disclosure includes detailed quarterly financial metrics (revenue of $645 million, net income of $125 million, EPS of $1.76), year-to-date performance, and raised full-year 2026 guidance for revenue and Adjusted EBITDA. This is a standard quarterly earnings release attached as Exhibit 99.1 and disclosed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →i3 Verticals issued a press release on August 6, 2026, announcing financial results for the three and nine months ended June 30, 2026, including revenue of $53.1 million (up 2.2% YoY), net income from continuing operations of $5.9 million, adjusted EBITDA of $13.3 million, diluted EPS, and revised fiscal 2026 guidance.
View raw filing on EDGAR →Arlo Technologies issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 28, 2026, disclosing record total revenue of $156 million (up 21% YoY), record adjusted EBITDA of $31 million, and GAAP EPS of $0.03. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →Nuveen Churchill Direct Lending Corp. disclosed its Q2 2026 financial results for the quarter ended June 30, 2026, reporting net investment income of $0.41 per share, net realized and unrealized losses, and NAV per share of $17.19. The earnings release was issued on August 6, 2026 and included consolidated financial statements and operational highlights.
View raw filing on EDGAR →BlackSky issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing total revenue of $33.3 million (up 50% YoY), record space-based intelligence revenue of $25 million, net loss of $20.8 million, and Adjusted EBITDA of $4.7 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Curaleaf's Q2 2026 financial results, including net revenue of $340.1 million (10% YoY growth), gross profit margin of 50%, net income of $12.5 million, and adjusted EBITDA of $70.1 million. The press release was issued on August 5, 2026, and is attached as Exhibit 99.1 to the 8-K filing, which is the standard format for Item 2.02 earnings disclosures. The results are material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →This is a clear earnings release disclosing Karat Packaging's Q2 2026 financial results, including record quarterly net sales of $136.3 million (up 9.9%), net income of $29.6 million (up 168.3%), and forward guidance for Q3 and full-year 2026. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →This is a clear earnings release disclosing Privia Health's Q2 2026 financial results, including net income of $9.0M (+236.7% YoY), adjusted EBITDA of $37.4M (+29.1% YoY), and updated full-year 2026 guidance raised across all key metrics. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →Immunovant issued a press release on August 6, 2026 announcing financial results for its fiscal first quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure reports net loss of $153.2 million, R&D expenses of $142.6 million, cash position of $797.8 million, and clinical development updates for IMVT-1402 across six indications. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →Kodiak Gas Services issued a press release on August 6, 2026, disclosing quarterly financial results for the period ended June 30, 2026, including net income of $52.0 million ($0.53 per diluted share), adjusted EBITDA of $216.8 million (21.7% increase YoY), and record discretionary cash flow of $163.3 million (40.2% increase YoY). The company also increased full-year 2026 guidance for adjusted EBITDA and discretionary cash flow. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →SpyGlass Pharma issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $19.9 million (vs. $8.7 million in Q2 2025), R&D expenses of $10.9 million, G&A expenses of $11.0 million, and cash position of $234.2 million. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →WM Technology announced its Q2 2026 financial results on August 6, 2026, disclosing revenue of $42.4 million, net income of $2.9 million, and adjusted EBITDA of $5.0 million. The full press release is furnished as Exhibit 99.1 and includes consolidated balance sheets, forward-looking guidance for Q3 2026, and management commentary on operating performance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →UWM released Q2 2026 financial results (ended June 30, 2026) disclosing total revenue of $888.0 million, net loss of $451.9 million, adjusted EBITDA of $185.9 million, and loan origination volume of $39.7 billion, along with announcement of a dividend suspension.
View raw filing on EDGAR →Viatris issued a press release on August 6, 2026, reporting second-quarter 2026 financial results for the period ended June 30, 2026, including total revenues of $3.8 billion, adjusted EBITDA of $1.2 billion, adjusted EPS of $0.69, and raised full-year 2026 guidance.
View raw filing on EDGAR →The Item 2.02 disclosure announces Shift4 Payments' financial results for the quarter ended June 30, 2026, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement, which is a material event affecting investor assessment of the registrant's operational and financial performance.
View raw filing on EDGAR →MP Materials issued a press release on August 6, 2026 announcing financial results for the three months ended June 30, 2026, disclosing consolidated revenue of $108.5 million (89% increase YoY), Adjusted EBITDA of $28.5 million, and net loss of $(20.3) million. The filing includes full financial statements (balance sheet, income statement, cash flows) and segment results, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 27, 2026). The Item 2.02 disclosure explicitly states that the Company "issued a press release, furnished as Exhibit 99.1...announcing the Company's financial results for the quarter ended June 27, 2026." The exhibit contains consolidated statements of operations, balance sheets, and cash flows with detailed financial metrics including revenue ($507.4M), net income, EPS, and segment performance data. The filing also includes forward guidance for fiscal year 2026.
View raw filing on EDGAR →Rocket Companies issued a press release on August 6, 2026 announcing Q2 2026 financial results, including total revenue of $2.78 billion, GAAP net income of $229 million, and adjusted net income of $441 million.
View raw filing on EDGAR →Unity Software Inc. disclosed its Q2 2026 financial results via press release on August 6, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes comprehensive financial statements showing total revenue of $546 million (up 24% YoY), strategic revenue of $486 million (up 38% YoY), adjusted EBITDA of $160 million with 29% margin, and free cash flow of $202 million. The CEO characterized it as "arguably the best quarter in Unity's history as a public company." This is a standard quarterly earnings release with full financial tables and forward guidance, clearly material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →Tarsus Pharmaceuticals issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states under Item 2.02 that the company "issued a press release, which, among other matters, sets forth the Company's results of operations for the three and six months ended June 30, 2026." The press release includes detailed quarterly and year-to-date financial metrics (product sales of $173.9M in Q2 2026 vs. $102.7M in Q2 2025, net loss of $18.6M vs. $20.3M, and updated full-year guidance of $685-705M), making this a standard earnings release disclosure.
View raw filing on EDGAR →Grindr issued a press release and shareholder letter on August 6, 2026, announcing financial results for Q2 2026 (quarter ended June 30, 2026). The disclosure includes Q2 revenue of $138 million (33% growth), net income of $18 million, and adjusted EBITDA of $58 million, along with raised full-year 2026 guidance. This is a standard earnings release disclosure under Item 2.02, with exhibits 99.1 and 99.2 containing the press release and shareholder letter respectively.
View raw filing on EDGAR →Sotera Health issued a press release on August 6, 2026, announcing financial results for the quarter ended June 30, 2026 (Q2 2026). The disclosure includes quarterly net revenues, net income, Adjusted EBITDA, Adjusted EPS, and segment-level performance metrics, along with an upward revision to full-year 2026 guidance. This is a standard earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is the designated Item for results of operations and financial condition.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly revenue of $51.4 million, net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million, along with updated full-year 2026 guidance raising Adjusted EBITDA guidance to $33–$35 million. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02, which is the standard Item for earnings announcements.
View raw filing on EDGAR →